New therapies for controlling atopic itch

Journal of Dermatology

Volumn 42, Issue 9, 2015, Pages 847-850

  Furue, Masutaka ^a   Kadono, Takafumi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atopic dermatitis; dorsal root ganglion; itch signal; new therapy; spinal cord

Indexed keywords

ANTIHISTAMINIC AGENT; ATIZORAM; CIM 331 ANTIBODY; CT 327; CYCLOSPORIN; DUPILUMAB; E 6005; EMOLLIENT AGENT; FEXOFENADINE; FLUOCINONIDE; JNJ 39758979; NALFURAFINE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ANTIPRURITIC AGENT;

AGRANULOCYTOSIS; ATOPIC DERMATITIS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; HUMAN; INTERNEURON; NOCICEPTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRURITUS; REVIEW; SKIN; SLEEP DISORDER; SOCIOECONOMICS; SPINAL CORD; SPINAL GANGLION; ULTRAVIOLET RADIATION; ANIMAL; COMPLICATION; DERMATITIS, ATOPIC;

ANIMALS; ANTIPRURITICS; DERMATITIS, ATOPIC; HUMANS; PRURITUS;

EID: 84940944932     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13060     Document Type: Review

References (40)

1. Takeuchi S, Esaki H, Furue M,. Epidemiology of atopic dermatitis in Japan. J Dermatol 2014; 41: 200-204.
2. Furue M, Yamazaki S, Jimbow K, et al,. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol 2011; 38: 310-320.
3. Saeki H, Furue M, Furukawa F, et al,. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563-577.
4. Rubel D, Thirumoorthy T, Soebaryo RW, et al,. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol 2013; 40: 160-171.
5. Akiyama T, Carstens E,. Neural processing of itch. Neuroscience 2013; 250: 697-714.
6. Roblin D, Yosipovitch G, Boyce B, et al,. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol 2015; 95: 542-548.
7. Takeuchi S, Yasukawa F, Furue M, Katz SI,. Collared mice: a model to assess the effects of scratching. J Dermatol Sci 2010; 57: 44-50.
8. Chamlin SL, Mattson CL, Frieden IJ, et al,. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005; 159: 745-750.
9. Noro Y, Omoto Y, Umeda K, et al,. Novel acoustic evaluation system for scratching behavior in itching dermatitis: rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients. J Dermatol 2014; 41: 233-238.
10. Tominaga M, Takamori K,. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol 2014; 41: 205-212.
11. Mochizuki H, Kakigi R,. Itch and brain. J Dermatol 2015; 42: 761-767.
12. Hachisuka J, Furue H, Furue M, Yoshimura M,. Responsiveness of C neurons in rat dorsal root ganglion to 5-hydroxytryptamine-induced pruritic stimuli in vivo. J Neurophysiol 2010; 104: 271-279.
13. Tekatas A, Arican O, Guler S, Aynacbox drawings light down and left O, Dincer N,. Pruritus: do Aδ fibers play a role? J Dermatol 2014; 41: 98-101.
14. Liu Q, Tang Z, Surdenikova L, et al,. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 2009; 139: 1353-1365.
15. Akiyama T, Carstens MI, Carstens E,. Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch. Pain 2010; 151: 378-383.
16. Sun YG, Chen ZF,. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007; 448: 700-703.
17. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF,. Cellular basis of itch sensation. Science 2009; 325: 1531-1534.
18. Mishra SK, Hoon MA,. The cells and circuitry for itch responses in mice. Science 2013; 340: 968-971.
19. Akiyama T, Tominaga M, Takamori K, Carstens MI, Carstens E,. Roles of glutamate, substance P, and gastrin-releasing peptide as spinal neurotransmitters of histaminergic and nonhistaminergic itch. Pain 2014; 155: 80-92.
20. Gutierrez-Mecinas M, Watanabe M, Todd AJ,. Expression of gastrin-releasing peptide by excitatory interneurons in the mouse superficial dorsal horn. Mol Pain 2014; 10: 79. doi: 10.1186/1744-8069-10-79.
21. Solorzano C, Villafuerte D, Meda K, et al,. Primary afferent and spinal cord expression of gastrin-releasing peptide: message, protein, and antibody concerns. J Neurosci 2015; 35: 648-657.
22. Foster E, Wildner H, Tudeau L, et al,. Targeted ablation, silencing, and activation establish glycinergic dorsal horn neurons as key components of a spinal gate for pain and itch. Neuron 2015; 85: 1289-1304.
23. Kawakami T, Soma Y,. Questionnaire survey of the efficacy of emollients for adult patients with atopic dermatitis. J Dermatol 2011; 38: 531-535.
24. Kamo A, Tominaga M, Negi O, Tengara S, Ogawa H, Takamori K,. Topical application of emollients prevents dry skin-inducible intraepidermal nerve growth in acetone-treated mice. J Dermatol Sci 2011; 62: 64-66.
25. Woods MT, Brown PA, Baig-Lewis SF, Simpson EL,. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. J Drugs Dermatol 2011; 10: 171-176.
26. Takeuchi S, Saeki H, Tokunaga S, et al,. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Ann Dermatol 2012; 24: 144-150.
27. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S,. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212-1221.
28. Otsuka A, Tanioka M, Nakagawa Y, et al,. Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis. Eur J Dermatol 2011; 21: 816-817.
29. Beck LA, Thaçi D, Hamilton JD, et al,. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.
30. Kataoka Y,. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol 2014; 41: 221-229.
31. Murata Y, Song M, Kikuchi H, et al,. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol 2015; 42: 129-139.
32. Hanifin JM, Chan SC, Cheng JB, et al,. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56.
33. Furue M, Kitahara Y, Akama H, et al,. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 2014; 41: 577-585.
34. Moustafa F, Feldman SR,. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J 2014; 20: 22608.
35. Cevikbas F, Wang X, Akiyama T, et al,. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 2014; 133: 448-460.
36. Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M,. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 2014; 69: 113-117.
37. Maier E, Werner D, Duschl A, Bohle B, Horejs-Hoeck J,. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J Immunol 2014; 193: 645-654.
38. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H,. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 1251-1257.
39. Akiyama T, Carstens MI, Piecha D, Steppan S, Carstens E,. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. Acta Derm Venereol 2015; 95: 147-150.
40. Tamari M, Hirota T,. Genome-wide association studies of atopic dermatitis. J Dermatol 2014; 41: 213-220.